Back to List View Graph View

BRAF

BRAF (B-Raf proto-oncogene, serine/threonine kinase) is a protein-coding gene that encodes a cytoplasmic serine/threonine-protein kinase in the RAF family.

Where the papers sit

22 papers from the last 6 months study BRAF directly · updated from PubMed 15 Nov 2026

  • BRAF-Mutant Melanoma Care

    Treatment of BRAF V600E melanoma is moving toward biomarker-guided sequencing of BRAF/MEK inhibition, surgery, and other disease-specific strategies rather than a single standard pathway. Progression-free survival, overall response, and survival vary with pTERT subtype, disease site, and treatment strategy, including brain and in-transit metastases. Circulating thymidine kinase and preoperative ctDNA are being evaluated to refine prognosis and treatment timing. Vemurafenib-based therapy also shows activity in BRAF-mutant hairy cell leukemia, extending the approach beyond melanoma.

    7 papers · 31.8%

  • BRAF Inhibitor Discovery

    Structure-guided discovery is generating new BRAF-directed scaffolds rather than focusing only on established inhibitors. Chalcone–quinazolinone, benzofuran–thiadiazole urea, and pyrimidinopyrimidine compounds are being screened against BRAF V600E, with dual VEGFR-2 activity and apoptosis as recurring goals. Molecular docking and dynamics support binding hypotheses, while caspase 9 links candidate activity to apoptotic signaling. The work remains early, with computational prioritization and biochemical or cellular validation preceding clinical translation.

    5 papers · 22.7%

  • BRAF-Driven Lung and Brain Tumors

    BRAF-altered lung and brain tumors are being defined by alteration type rather than treated as one molecular entity. BRAF fusions create TKI vulnerabilities but can also mediate resistance, while post-osimertinib EGFR-mutant NSCLC is prompting osimertinib–selumetinib combination testing. Comprehensive genomic profiling and consensus guidance are central to selecting therapy across non-small-cell lung cancer and glioma. Cutaneous toxicity from BRAF/MEK inhibitors remains a practical constraint, leaving optimal sequencing and combination durability open.

    4 papers · 18.2%

  • Others — Cancer Biomarkers and Therapeutics

    Mutant-BRAF degradation, colorectal cancer prognosis, image-derived biomarkers, and treatment guidance appear together without a single disease focus. The recurring theme is molecular stratification: molecular responses, systemic inflammation, histopathology features, and defined genomic alterations are used to separate risk or treatment benefit. Evidence ranges from in silico and preliminary in vitro work to real-world survival analyses, canine therapy, and pediatric thyroid guidance. No consistent therapeutic direction emerges, and validation across cohorts remains the shared unmet need.

    6 papers · 27.3%

Papers

The 22 papers from the last 6 months that study BRAF directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

BRAF-Mutant Melanoma Care (7)
  1. Pre-operative circulating tumour DNA in high-risk primary cutaneous melanoma: prospective feasibility in molecular pathology. Acta oncologica (Stockholm, Sweden) · 9 Sept 2026 PMID 42714248
  2. Circulating Thymidine Kinase Activity Predicts Survival and Optimal Treatment Sequencing in BRAF-Mutated Metastatic Melanoma in the SECOMBIT Trial. Clinical cancer research : an official journal of the American Association for Cancer Research · 4 Aug 2026 PMID 42550831
  3. Impact of BRAF inhibitors on surgical outcomes in melanoma brain metastases: Evidence from a multicenter observational study. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 15 Jul 2026 PMID 42456530
  4. Association Between pTERT Promoter Mutation Subtypes and Survival Outcomes in BRAF-Mutant Metastatic Melanoma Treated With BRAF/MEK Inhibitors: An Exploratory Study. International journal of dermatology · 8 Jul 2026 PMID 42415286
  5. Response and survival in unresectable in-transit metastatic melanoma according to treatment strategy. European journal of cancer (Oxford, England : 1990) · 23 Jun 2026 PMID 42335571
  6. Low-dose vemurafenib plus rituximab in frontline and relapsed or refractory hairy cell leukemia: the Scripps regimen. Blood advances · 17 Jun 2026 PMID 42308249
  7. Secondary BRAF-mutated histiocytic/dendritic cell sarcoma transdifferentiated from follicular lymphoma with prolonged response to BRAF/MEK inhibition and subsequent evolution to high-grade B-cell lymphoma. Journal of clinical pathology · 9 Jun 2026 PMID 42264920
BRAF Inhibitor Discovery (5)
  1. Discovery of chalcone-quinazolinone hybrids as BRAF kinase inhibitors with potential anticancer activity: Design, synthesis, biological evaluation, and molecular modeling studies. Bioorganic chemistry · 5 Nov 2026 PMID 42987746
  2. Novel benzofuran-1,3,4-thiadiazole aryl urea hybrids as dual VEGFR-2/BRAF inhibitors: anticancer activity, apoptosis induction, and molecular modeling studies. Bioorganic & medicinal chemistry · 6 Aug 2026 PMID 42561779
  3. DF-S4: Disentangled FiLM-Conditioned Molecular Generation Using the S4 Architecture. Journal of chemical information and modeling · 23 Jul 2026 PMID 42489643
  4. Unveiling Large-Scale Kinase-Centric Protein-Protein Interactions through a Knowledge-Informed Workflow. Journal of chemical information and modeling · 10 Jul 2026 PMID 42427025
  5. Design and Synthesis of Pyrimidino[4,5-d]Pyrimidine-Based Compounds as Potent B-RAF V600E Inhibitors. ChemMedChem · 28 May 2026 PMID 42208521
BRAF-Driven Lung and Brain Tumors (4)
  1. BRAF fusions define therapeutic vulnerability and tyrosine kinase inhibitor resistance in non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) · 3 Aug 2026 PMID 42546514
  2. BRAF-altered glioma in adults and children: A Society for Neuro-Oncology (SNO) and European Society for Neuro-Oncology (EANO) consensus review on clinical management and future directions. Neuro-oncology · 9 Jun 2026 PMID 42261252
  3. Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD. European journal of cancer (Oxford, England : 1990) · 27 May 2026 PMID 42202477
  4. Cutaneous Adverse Drug Reactions Associated With BRAF and MEK Inhibitors: A Real-World Analysis of WHO Pharmacovigilance Data. Clinical pharmacology and therapeutics · 24 May 2026 PMID 42177750
Others — Cancer Biomarkers and Therapeutics (6)
  1. In silico prioritization with preliminary in vitro assessment of UV-328-associated molecular responses in colorectal cancer cells. Functional & integrative genomics · 5 Nov 2026 PMID 42986495
  2. Systemic inflammation and prognosis in patients with RAS/BRAF wild-type metastatic colorectal cancer receiving anti-EGFR therapy: A real-world cohort study. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 26 Sept 2026 PMID 42798176
  3. Sorafenib/piroxicam therapy with biomarker-defined survival benefit in canine muscle-invasive urothelial carcinoma. Scientific reports · 2 Sept 2026 PMID 42680778
  4. Updated Dutch 2026 pediatric differentiated thyroid carcinoma guideline: aligning with Europe. European journal of endocrinology · 23 Jul 2026 PMID 42489130
  5. A molecular glue to take down mutant BRAF. Science signaling · 14 Jul 2026 PMID 42447212
  6. Spatial biomarker discovery via interpretable semantic learning in histopathology. Cancer cell · 11 Jun 2026 PMID 42276049

By study type

Clinical trials (2)
  1. Circulating Thymidine Kinase Activity Predicts Survival and Optimal Treatment Sequencing in BRAF-Mutated Metastatic Melanoma in the SECOMBIT Trial. Clinical cancer research : an official journal of the American Association for Cancer Research · 4 Aug 2026 PMID 42550831
  2. Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD. European journal of cancer (Oxford, England : 1990) · 27 May 2026 PMID 42202477
Observational studies and case reports (9)
  1. Systemic inflammation and prognosis in patients with RAS/BRAF wild-type metastatic colorectal cancer receiving anti-EGFR therapy: A real-world cohort study. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 26 Sept 2026 PMID 42798176
  2. Pre-operative circulating tumour DNA in high-risk primary cutaneous melanoma: prospective feasibility in molecular pathology. Acta oncologica (Stockholm, Sweden) · 9 Sept 2026 PMID 42714248
  3. BRAF fusions define therapeutic vulnerability and tyrosine kinase inhibitor resistance in non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) · 3 Aug 2026 PMID 42546514
  4. Impact of BRAF inhibitors on surgical outcomes in melanoma brain metastases: Evidence from a multicenter observational study. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 15 Jul 2026 PMID 42456530
  5. Association Between pTERT Promoter Mutation Subtypes and Survival Outcomes in BRAF-Mutant Metastatic Melanoma Treated With BRAF/MEK Inhibitors: An Exploratory Study. International journal of dermatology · 8 Jul 2026 PMID 42415286
  6. Response and survival in unresectable in-transit metastatic melanoma according to treatment strategy. European journal of cancer (Oxford, England : 1990) · 23 Jun 2026 PMID 42335571
  7. Low-dose vemurafenib plus rituximab in frontline and relapsed or refractory hairy cell leukemia: the Scripps regimen. Blood advances · 17 Jun 2026 PMID 42308249
  8. Secondary BRAF-mutated histiocytic/dendritic cell sarcoma transdifferentiated from follicular lymphoma with prolonged response to BRAF/MEK inhibition and subsequent evolution to high-grade B-cell lymphoma. Journal of clinical pathology · 9 Jun 2026 PMID 42264920
  9. Cutaneous Adverse Drug Reactions Associated With BRAF and MEK Inhibitors: A Real-World Analysis of WHO Pharmacovigilance Data. Clinical pharmacology and therapeutics · 24 May 2026 PMID 42177750
Human data, design not indexed (4)
  1. Updated Dutch 2026 pediatric differentiated thyroid carcinoma guideline: aligning with Europe. European journal of endocrinology · 23 Jul 2026 PMID 42489130
  2. A molecular glue to take down mutant BRAF. Science signaling · 14 Jul 2026 PMID 42447212
  3. Unveiling Large-Scale Kinase-Centric Protein-Protein Interactions through a Knowledge-Informed Workflow. Journal of chemical information and modeling · 10 Jul 2026 PMID 42427025
  4. Spatial biomarker discovery via interpretable semantic learning in histopathology. Cancer cell · 11 Jun 2026 PMID 42276049
Preclinical: animal, cell and lab studies (6)
  1. Discovery of chalcone-quinazolinone hybrids as BRAF kinase inhibitors with potential anticancer activity: Design, synthesis, biological evaluation, and molecular modeling studies. Bioorganic chemistry · 5 Nov 2026 PMID 42987746
  2. In silico prioritization with preliminary in vitro assessment of UV-328-associated molecular responses in colorectal cancer cells. Functional & integrative genomics · 5 Nov 2026 PMID 42986495
  3. Sorafenib/piroxicam therapy with biomarker-defined survival benefit in canine muscle-invasive urothelial carcinoma. Scientific reports · 2 Sept 2026 PMID 42680778
  4. Novel benzofuran-1,3,4-thiadiazole aryl urea hybrids as dual VEGFR-2/BRAF inhibitors: anticancer activity, apoptosis induction, and molecular modeling studies. Bioorganic & medicinal chemistry · 6 Aug 2026 PMID 42561779
  5. DF-S4: Disentangled FiLM-Conditioned Molecular Generation Using the S4 Architecture. Journal of chemical information and modeling · 23 Jul 2026 PMID 42489643
  6. Design and Synthesis of Pyrimidino[4,5-d]Pyrimidine-Based Compounds as Potent B-RAF V600E Inhibitors. ChemMedChem · 28 May 2026 PMID 42208521
Unclassified: not yet indexed with MeSH (1)
  1. BRAF-altered glioma in adults and children: A Society for Neuro-Oncology (SNO) and European Society for Neuro-Oncology (EANO) consensus review on clinical management and future directions. Neuro-oncology · 9 Jun 2026 PMID 42261252